ACE-031, at a dose of 1mg, is presently generating considerable interest across Europe. Initial clinical trials in countries such as Germany and its surrounding areas, France and its neighbors, and the UK have revealed encouraging results in treating particular brain ailments. Regulatory authorities across the continent are closely reviewing the da